Regencell Bioscience (NASDAQ:RGC) Trading 22.5% Higher – What’s Next?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price shot up 22.5% on Wednesday . The stock traded as high as $27.84 and last traded at $28.1410. 178,945 shares traded hands during trading, a decline of 61% from the average session volume of 454,018 shares. The stock had previously closed at $22.97.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Regencell Bioscience Stock Performance

The firm’s fifty day moving average price is $28.99 and its 200 day moving average price is $20.74.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Squarepoint Ops LLC acquired a new stake in shares of Regencell Bioscience during the 2nd quarter valued at about $1,701,000. Geode Capital Management LLC increased its holdings in Regencell Bioscience by 5,637.5% in the second quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock worth $6,664,000 after buying an additional 384,250 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Regencell Bioscience in the second quarter worth approximately $768,000. Seven Fleet Capital Management LP bought a new position in Regencell Bioscience during the fourth quarter valued at approximately $92,000. Finally, Vident Advisory LLC raised its position in Regencell Bioscience by 65.7% during the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after acquiring an additional 11,866 shares in the last quarter. Hedge funds and other institutional investors own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.